The estimated Net Worth of Sridhar Kosaraju is at least $27.8 Millón dollars as of 14 September 2022. Mr. Kosaraju owns over 10,000 units of 10x Genomics stock worth over $675,774 and over the last 8 years he sold TXG stock worth over $25,512,941. In addition, he makes $1,633,700 as Independent Director at 10x Genomics.
Sign up
Mr. Kosaraju TXG stock SEC Form 4 insiders trading
Sridhar has made over 41 trades of the 10x Genomics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of TXG stock worth $114,800 on 14 September 2022.
The largest trade he's ever made was selling 25,000 units of 10x Genomics stock on 15 November 2016 worth over $1,626,750. On average, Sridhar trades about 4,274 units every 32 days since 2016. As of 14 September 2022 he still owns at least 30,578 units of 10x Genomics stock.
You can see the complete history of Mr. Kosaraju stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sridhar Kosaraju biography
Sridhar Kosaraju serves as Independent Director of the Company. He has served on our board of directors since April 2019. Mr. Kosaraju has served as President of Penumbra since August 2019. At Penumbra, Mr. Kosaraju previously served as Chief Financial Officer from May 2015 to November 2019 and as Head of Strategy from May 2015 to August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC from 1999 to May 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan’s equity capital markets group in 2006, Mr. Kosaraju served in various practice groups at J.P. Morgan, including Equity Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. He received a B.S. from Massachusetts Institute of Technology in 1999.
What is the salary of Sridhar Kosaraju?
As the Independent Director of 10x Genomics, the total compensation of Sridhar Kosaraju at 10x Genomics is $1,633,700. There are 2 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
How old is Sridhar Kosaraju?
Sridhar Kosaraju is 42, he's been the Independent Director of 10x Genomics since 2019. There are 16 older and no younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
What's Sridhar Kosaraju's mailing address?
Sridhar's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Insiders trading at 10x Genomics
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F... y Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
What does 10x Genomics's logo look like?
Complete history of Mr. Kosaraju stock trades at Nevro Corp, Penumbra Inc y 10x Genomics
10x Genomics executives and stock owners
10x Genomics executives and other stock owners filed with the SEC include:
-
Serge Saxonov,
Chief Executive Officer, Co-Founder, Director -
Benjamin Hindson,
President, Co-Founder, Chief Scientific Officer, Director -
Sridhar Kosaraju,
Independent Director -
Shehnaaz Suliman,
Independent Director -
Eric Whitaker,
General Counsel -
Bryan Roberts,
Independent Director -
Dr. Serge Saxonov Ph.D.,
Co-Founder, CEO & Director -
Justin McAnear,
Chief Financial Officer -
Dr. Benjamin J. Hindson Ph.D.,
Co-Founder, Pres, Chief Scientific Officer & Director -
Bradford J. Crutchfield,
Chief Commercial Officer -
Ruth De Backer,
Chief Bus. Officer -
Justin J. McAnear,
Chief Financial Officer -
John Stuelpnagel,
Independent Chairman of the Board -
Mathai Mammen,
Independent Director -
Kimberly Popovits,
Independent Director -
Bradford Crutchfield,
Chief Commercial Officer -
Jean Philibert,
Chief People Officer -
Sam Ropp,
Sr. VP of Global Sales -
Jonathan Schimmel,
VP of Global Support & Sales Operations -
Eric S. Whitaker,
Gen. Counsel -
Cassie Corneau,
Mang. of Investor Relations and Strategic Fin. -
Paul W. Wyatt,
Sr. VP of Operations -
Capital Management, Llc Pal...,
-
Associates Vi, L.P.Venrock ...,
-
Vision Fund (Aiv M2) L.P.Sb...,
-
Capital Management I, Llc F...,
-
Sarah A. Teichmann,
-
James Wilbur,
Chief Commercial Officer -
Alan Mateo,